Withus Pharmaceutical
위더스제약 · 330350
Health Care Pharmaceuticals · KOSDAQ
Market cap US$64.2M (₩88.6B)
Overview
Withus Pharmaceutical makes finished prescription medicines, including treatments for high blood pressure, high cholesterol, hardening of the arteries, bone and joint conditions, digestive disorders, infections, and central-nervous-system conditions, targeting the chronic diseases common in an ageing population.
Its products are distributed through a nationwide sales network to hospitals, clinics, and pharmacies across South Korea. Listed on KOSDAQ, South Korea's tech and small-cap board, the company earns the largest share of its revenue from cardiovascular medicines, with its cholesterol-lowering tablet Atoren (atorvastatin), a generic version of a widely used branded drug, as its leading product.
Summary is AI-generated and may contain errors · figures from DART filings
Financials
Source: DART · FY ending Dec · latest FY2025Revenue
- FY2023US$58.1M
- FY2024US$74.4M
- FY2025US$77.1M
Operating profit
- FY2023US$5.7M
- FY2024US$4.1M
- FY2025US$4.1M
Net income
- FY2023US$5.8M
- FY2024US$3.5M
- FY2025US$3.6M
Key ratios (FY2025)
Why it matters
Alongside its own branded generics, the company also manufactures finished medicines on behalf of other pharmaceutical firms under contract manufacturing (CMO) arrangements, a segment it is actively expanding.
Price charts coming soon
Interactive price history isn't here yet. Would you use it?